In Brief This Week: Quest; Abbott; Siemens; Albert Einstein College of Medicine, New York Genome Center; Sigma-Aldrich; Waters; More | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics completed the sale of its HemoCue diagnostics product business to Danaher company Radiometer for about $300 million. The deal was originally announced in February as part of Quest's plans to divest certain non-core assets to focus on its diagnostic information services business. Quest will use proceeds from the sale to repurchase about $300 million of its shares as part of a buyback program, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.